AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00721110
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
Trial: NCT00721110
Drug: Ketamine + Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: both Ketamine and Lidocaine will be given
Trial: NCT00257010
Drug: Almotriptan Malate
RxNorm normalized name: Almotriptan Malate
DrugBank: Almotriptan (DB00918)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
Trial: NCT02624492
Drug: BI 836826
RxNorm normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02624492
Drug: GemOx
RxNorm normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02624492
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01538485
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly dose (based on 70IU KG body weight/day)
Trial: NCT03321448
Drug: TMTP1-ICG
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of SLN
Trial: NCT03321448
Drug: ICG
RxNorm normalized name: ICG136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of SLN
Trial: NCT00364689
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00364689
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02562326
Drug: BioChaperone insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection immediately before the start of the individualised standard meal
Trial: NCT00305942
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan 4mg/m2 IV on days 1, 8.
Trial: NCT00305942
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC=5 IV day 1 only .
Trial: NCT03154567
Drug: Yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
Trial: NCT01681849
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Trial: NCT02465112
Drug: In111-Pentetréotide
RxNorm normalized name: pentetreotide
DrugBank: Pentetreotide (DB12602)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01163786
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
Trial: NCT01950039
Drug: Betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine or placebo administered orally in divided doses over 12 weeks
Trial: NCT04074837
Drug: NNI-362
RxNorm normalized name: NNI-351
DrugBank: NNI-351 (DB18048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNI-362 small molecule in liquid suspension.
Trial: NCT00873886
Drug: Oseltamivir (Tamiflu)
RxNorm normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected.
Trial: NCT03338920
Drug: sumatriptan nasal powder
RxNorm normalized name: sumatriptan Nasal Powder
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal powder administered via nosepiece
Trial: NCT02274233
Drug: SP-420
RxNorm normalized name: SP-420
DrugBank: SP-420 (DB16069)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00087035
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
Trial: NCT00087035
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be taken at a starting daily dose of 150mg
Trial: NCT01586715
Drug: Adipose-derived stem cells without expanded
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Trial: NCT02839928
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
Trial: NCT02839928
Drug: EMLA
RxNorm normalized name: EMLA
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04403685
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
Trial: NCT02644057
Drug: Milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Trial: NCT02644057
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Trial: NCT01415687
Drug: Polyethylene Glycol-Based Lavage
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours.
Trial: NCT01415687
Drug: Pico-Salax (Magnesium Citrate) plus Bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre.
Trial: NCT01942460
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03792074
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab Injection
Trial: NCT03792074
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel Injection
Trial: NCT03792074
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin injection
Trial: NCT00003680
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003680
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00049946
Drug: talnetant
RxNorm normalized name: Talnetant
DrugBank: Talnetant (DB06429)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00049946
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00660231
Drug: bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
Trial: NCT00660231
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
Trial: NCT02825563
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the fasting state
Trial: NCT02825563
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the high fat diet
Trial: NCT02392169
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients used Retina or Concerta twice a day lasting for one year.
Trial: NCT00003670
Drug: arzoxifene hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04057014
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic given at different dosages and durations.
Trial: NCT00713154
Drug: MTS-01
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
Trial: NCT03610022
Drug: Treatment with vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
Trial: NCT04655976
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered.
Trial: NCT04275518
Drug: APG-115
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-115 orally once daily from Days 1 to 7 every 28 days.
Trial: NCT04275518
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
Trial: NCT04275518
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Trial: NCT03673072
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
Trial: NCT03673072
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
Trial: NCT02353598
Drug: Crenezumab dose level 1
RxNorm normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Trial: NCT02353598
Drug: Crenezumab dose level 2
RxNorm normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Trial: NCT02353598
Drug: Crenezumb dose level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Trial: NCT03121547
Drug: Tapentadol 50 mg Oral Tablet
RxNorm normalized name: tapentadol 50 MG Oral Tablet
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet administered
Trial: NCT03121547
Drug: Tramadol Hydrochloride 100 mg Extended Release Oral Tablet
RxNorm normalized name: tramadol hydrochloride 100 MG Extended Release Oral Tablet
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet administered
Trial: NCT01979484
Drug: PPI-668 capsule
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01979484
Drug: PPI-668 tablet
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02298946
Drug: AMP-224
RxNorm normalized name: AMP-224
DrugBank: AMP-224 (DB15767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Trial: NCT00423865
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
Trial: NCT00423865
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
Trial: NCT03555994
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide administered subcutaneously
Trial: NCT03110510
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg/m2
Trial: NCT00755287
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: starting dose 10 IU daily
Trial: NCT00755287
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As prescribed
Trial: NCT00755287
Drug: taspoglutide
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg once weekly
Trial: NCT00755287
Drug: taspoglutide
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
Trial: NCT05076474
Drug: Orlistat 60mg Cap
RxNorm normalized name: ORLISTAT 60MG CAP
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
Trial: NCT00009542
Drug: kava (Piper methysticum)
RxNorm normalized name: KAVA
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02412436
Drug: Depot medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Depot medroxyprogesterone acetate intramuscular injection
Trial: NCT01887197
Drug: mannitol inhalation powder
RxNorm normalized name: mannitol Inhalation Powder
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mannitol inhalation powder
Trial: NCT00611286
Drug: clopidogrel treatment after bare metal stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
Trial: NCT00611286
Drug: clopidogrel treatment after bare metal stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
Trial: NCT00611286
Drug: clopidogrel after zotarolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
Trial: NCT00611286
Drug: clopidogrel after paclitaxel-eluting stent implantation
RxNorm normalized name: Paclitaxel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
Trial: NCT00611286
Drug: clopidogrel after everolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
Trial: NCT00611286
Drug: clopidogrel after zotarolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Trial: NCT00611286
Drug: clopidogrel after paclitaxel-eluting stent implantation
RxNorm normalized name: Paclitaxel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Trial: NCT00611286
Drug: clopidogrel after everolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Trial: NCT02462629
Drug: BLZ-100
RxNorm normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619801
Drug: Levocetirizine
RxNorm normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
Trial: NCT03923998
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
Trial: NCT01346917
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
Trial: NCT02685852
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide at a dose of 5 mcg
Trial: NCT02685852
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose at a dose of 25 mg
Trial: NCT02685852
Drug: Exenatide Placebo
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Exenatide
Trial: NCT02685852
Drug: Acarbose Placebo
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Acarbose
Trial: NCT00674063
Drug: alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV